In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.
Analysts have given Abbott Laboratories (ABT), Boston Scientific (BSX), and Johnson & Johnson (JNJ) a mean rating of 1.8, 1.52, and 2.32, respectively, and target prices of $78.94, $41.96, and $146.78, respectively.
Baxter International’s enterprise value is $36.32 billion, while its enterprise value-to-revenues ratio is 3.28. The stock is trading at a forward PE multiple of 20.13x. Baxter International’s price-to-sales ratio is 3.19, while its price-to-book value ratio is 3.85. Abbott Laboratories, Boston Scientific, and Johnson & Johnson’s price-to-book value ratios stand at 4.05, 6.09, and 6.0, respectively.
Baxter International’s current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 2.60. Abbott Laboratories, Boston Scientific, and Johnson & Johnson’s current ratios are 1.40, 0.80, and 1.70, respectively.
Baxter International’s cash per share stands at $5.34. Abbott Laboratories, Boston Scientific, and Johnson & Johnson’s cash per share are $4.29, $0.12, and $7.22, respectively.